Table 1:
Demographics and Participant Characteristics
| High SWS (N3% > 15.8%) |
Low SWS (N3% ≤ 15.8%) |
t/U | p | |
|---|---|---|---|---|
| 16 | 16 | |||
| Age | ||||
| Mean ± SD | 65.12 ± 6.02 | 66.69 ± 6.76 | 0.69 | 0.49 |
| Range | 54 – 77 | 53 – 75 | ||
| Sex: N (%) | ||||
| Male | 6 (37.5) | 12 (75.0) | −2.24 | 0.033 |
| Female | 10 (62.5) | 4 (25.0) | ||
| Education (years) | ||||
| Median (IQR) | 16.00 (14.5 – 18.0) | 14.00 (14.00 – 16.0) | 85.5 | 0.11 |
| Duration of Disease (DOD) (years) | ||||
| Mean ± SD | 6.75 ± 3.97 | 7.75 ± 4.27 | −0.69 | 0.50 |
| Range | 1 – 15 | 1 – 15 | ||
| Hoehn & Yahr | ||||
| Mean ± SD | 2.00 ± 0.59 | 2.00 ± 0.63 | −0.30 | 0.76 |
| Range | 1 – 3* | 1 – 3 | ||
| Levodopa Equivalent Dose (LED) | ||||
| Median (IQR) | 500.00 (334.87 – 614.25) | 849.37 (603.12 – 1043.50) | 51.0 | 0.003 |
| Taking medication known to affect SWS: N (%) | 2 (12.5) | 2 (12.5) | 0 | 1.0 |
| Taking medications that affect sleep**: N (%) | 8 (50.0) | 8 (50.0) | 0 | 1.0 |
| MDS-UPDRS | ||||
| Part I | ||||
| Median (IQR) | 10.00 (5.5 – 12.5) | 9.5 (6.25 – 13.0) | 122.0 | 0.84 |
| Part II | ||||
| Mean ± SD | 10.81 ± 5.81 | 11.94 ± 5.87 | 0.54 | 0.59 |
| Range | 2 – 20 | 2 – 24 | ||
| Part III | ||||
| Mean ± SD | 30.56 ± 12.77 | 30.62 ± 14.03 | 0.01 | 0.99 |
| Range | 4 – 48 | 4 – 52 | ||
| Part IV* | ||||
| Median (IQR) | 3.00 (0.0 – 4.0)* | 4.00 (2.0 – 7.0) | 69.0 | 0.04 |
| Total* | ||||
| Mean ± SD | 53.73 ± 18.61 | 57.44 ± 16.30 | 0.59 | 0.56 |
| Range | 24 – 83* | 24 – 92 |
*
MDS-UPDRS, N=15 (missing Part IV and Total Score for 1 participant)
**
Medications potentially affecting sleep include benzodiazepines, non-benzodiazepine hypnotics, narcotics, antipsychotics, melatonin, and sedating antidepressants such as trazodone.
Median and IQR (interquartile range) are reported for variables not normally distributed with group differences examined using Mann-Whitney U, exact significance test.